Not currently enrolling

A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia

Assess the safety and tolerability of ZN-d5 and ZN-c3 when administered in combination and ZN-c3 monotherapy, in subjects with AML. Determine the MTD and RP2D for ZN-d5 and ZN-c3 when administered in combination to subjects with AML.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Joshua Zeidner
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

23-0246

ClinicalTrials.gov

NCT05682170

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.